Abstract: N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, or a stereoisomer thereof which is a novel compound exhibiting excellent inhibitory activity against IRAK-4, can be used without side effects for efficient prevention and treatment of diseases mediated by IRAK-4 receptors, particularly autoimmune diseases or lymphomas.
Type:
Application
Filed:
September 29, 2020
Publication date:
November 3, 2022
Applicant:
KAINOS MEDICINE, INC.
Inventors:
Jaeuk CHUNG, Sunmi KIM, Hanyang CHO, Jiyoung MIN
Abstract: A salt compound of 4-(2-((4-bromophenyl)thio)acetamido)-1-phenethyl-1H-pyrazole-3-carboxylic acid is disclosed. Also disclosed are methods for making the salt compound and formulations of the salt compound into dosage forms for clinical use.
Abstract: The present invention provides mutual prodrugs comprising anti-cancer nucleosides and short chain fatty acids; methods for production of the mutual prodrugs; methods of treatment comprising administration of the mutual prodrugs; and pharmaceutical compositions comprising the mutual prodrugs. Further, the mutual prodrugs of the present invention can be used as therapeutic agents for the treatment of cancer diseases and conditions.
Abstract: Provided is a novel compound having bromodomain and extra terminal domain (BET) protein inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of precancerous transformation or cancer.
Abstract: Provided is a novel compound having bromodomain and extra terminal domain (BET) protein inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of precancerous transformation or cancer.
Abstract: The invention provides a novel compound having activity against diacylglycerol O-acyltransferase type 1 (DGAT1); a pharmaceutical composition for preventing or treating a disease, disorder or condition modulated by inhibition of DGAT1 comprising said compound; a method for preventing or treating a disease, disorder or condition modulated by inhibition of DGAT1 in an individual comprising administering said compound to the individual in need thereof; and a use of said compound for the manufacture of a medicament for preventing or treating a disease, disorder or condition modulated by DGAT1 inhibition.
Abstract: The present invention relates to novel 2-carbonyl-3-acyl-1,3-thiazolidines having a ?-amino group on the acyl chain, in free, prodrug form or pharmaceutically acceptable salt thereof, including their enantiomers, diastereomers and racemates, as efficient inhibitors against DPP-IV. The invention further relates to the pharmaceutical compositions comprising the disclosed compounds. The present invention also relates to methods for preparing the disclosed compounds and for treating DPP-IV-mediated diseases.
Type:
Application
Filed:
January 16, 2008
Publication date:
February 25, 2010
Applicants:
Kainos Medicine, Inc, Korea Research Institute of Chemical Technology, Yungjin Pharmaceutical Company, Ltd
Inventors:
Sung Soo Kim, Jin Hee Ahn, Hyae Gyeong Cheon, Sang Dal Rhee, Nam Sook Kang, Ki Young Kim, Seung Kyu Kang, Won Hoon Jung, Sung Gyu Kim, Sun Young Kim, Jae Hong Kweon, Sang Kwon Sohn, Min Ki Shin, Ni Na Ha